Westborough, Massachusetts-based Miach Orthopaedics, Inc. has announced that Michael J. McNulty will join the company as Vice President of Sales and Marketing.
McNulty New VP of Sales + Marketing at Miach Orthopaedics
1 min read Premium comments
#miachorthopaedicsSecondary#michaelmcnulty
Miach Orthopaedics is a privately held company focused on the development of bioengineered surgical implants for connective tissue repair.
McNulty has over 20 years of global medical device commercial experience. In his most recent role, McNulty served as senior director of sales in the Biologics Division at Smith & Nephew after the company acquired Rotation Medical, where he served as vice president of sales and marketing. McNulty also spent time at Arstasis, Cordias, and as an officer in the Armor Cavalry Branch of the United States Army.
McNulty will lead Miach’s commercialization and sales efforts for the Bridge-Enhanced® ACL Repair (BEAR®) Implant, an investigational device designed for anterior cruciate ligament (ACL) repair. The BEAR technology uses a proprietary bio-engineered bridging scaffold to facilitate healing of the torn ACL.
The BEAR Implant is intended to restore more normal anatomy and function of the knee, and thus enable a higher percentage of patients to get back to activities they enjoy. The BEAR II pivotal study completed enrollment, and the BEAR implant is only available in ongoing FDA-approved clinical trials.
Martha Shadan, company president and CEO, said of McNulty, “Mike is a talented commercial leader who is skilled at hiring, developing and motivating his team to consistently deliver exceptional sales performance. We have worked together in the past to build a successful business based around a totally new orthopaedic treatment, and I look forward to partnering with him to leverage our experience as we begin planning for the launch of the BEAR Implant.”
OTW spoke with McNulty who said, “I am excited to reunite with Martha Shadan to bring another breakthrough in orthopaedic medicine to patients in the U.S. Our collective insights from Rotation Medical in bringing a disruptive treatment to market will be invaluable as we work to evolve the treatment of ACL [anterior cruciate ligament] tears from reconstruction to repair with the BEAR Implant.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.